


or a pharmaceutically acceptable salt thereof and the taxane are to be administered at doses lower than their maximum tolerable doses.

~~14. A kit comprising a compound of the formula~~




~~or a pharmaceutically acceptable salt thereof and a taxane.~~

~~15. The kit of claim 14 wherein the taxane is selected from the group consisting of docetaxel and paclitaxel.~~

~~16. The kit of claim 15 wherein the taxane is docetaxel.~~


~~17. The kit of claim 15 wherein the taxane is paclitaxel.~~

~~18. The kit of claim 14 wherein the compound of the formula~~




~~or a pharmaceutically acceptable salt thereof and the taxane are in therapeutically effective amounts.~~

~~19. The kit of claim 14 wherein the compound of the formula~~




~~or a pharmaceutically acceptable salt thereof and the taxane are in sterile containers or packages.~~

~~20. The kit of claim 14 wherein the compound of the formula~~




~~or a pharmaceutically acceptable salt thereof and the taxane have a purity of at least 90% based on weight percentage.~~

~~21. The kit of claim 14 wherein the compound of the formula~~




~~or a pharmaceutically acceptable salt thereof and the taxane have a purity of at least 95% based on weight percentage.~~

~~22. The kit of claim 14 wherein the compound of the formula~~




~~or a pharmaceutically acceptable salt thereof is in the form of a reconstitutable lyophilizate.~~

~~23. The kit of claim 14 wherein the compound of the formula~~



~~or a pharmaceutically acceptable salt thereof and the taxane are in sterile, pyrogen-free aqueous solutions.~~


14 ~~24~~. Use of a dose of a compound of the formula



or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treatment of non-small cell lung cancer, wherein the medicament is to be administered to a patient in an intravenous bolus injection two days a week during weeks one and two of a three week cycle of therapy; and

wherein the medicament is to be administered with a dose of docetaxel over one hour on day one of the three week cycle of therapy.


15 ~~25~~. The use of claim 14 ~~24~~ wherein the dose of the compound of the formula



or a pharmaceutically acceptable salt thereof is 2.5 mg.

16 ~~26~~. The use of claim 14 ~~24~~ wherein the dose of docetaxel is 75 mg/m^2 of body surface area.

17 ~~27~~. The use of claim 1 wherein the compound of the formula



or a pharmaceutically acceptable salt thereof and the taxane are in sterile containers or packages.